港股早評:三大指數低開,生物醫藥股回調,黃金股集體強勢
非農人數低於預期,上週五美股大幅下挫!連續回調的港股三大指數再度低開,恒指跌0.31%,國指跌0.35%,恒生科技指數跌0.66%。盤面上,大型科技股升跌不一,快手、阿里巴巴跌超1%,京東、百度小幅下跌,騰訊、網易飄紅;特朗普要求降低藥品價格上週五美股醫藥股大跌,連續上升的港股生物醫藥股多數回調,復宏漢霖跌近4%,泰格醫藥、藥明康德、信達生物、諾誠健華均有跌幅;汽車股持續走低,比亞迪股份跌近3%,內險股、鋼鐵股、電力股、蘋果概念股多數走低。另一方面,避險情緒升温,黃金股集體上升,靈寶黃金、招金礦業升超3%,海運股、中醫藥股、茶飲料概念股多數上升,德翔海運升超6%,茶百道升超1%。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.